Virtual healthcare services, or telehealth, are rapidly becoming a standard of care in the expanding digital healthcare space ...

Novo Nordisk just killed its deal with Hims & Hers. But Hims might come out stronger after this development. Read why the ...

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

T he ad that Hims & Hers Health plans to air during the Super Bowl comes at you with rapid-fire visual overload—a giant jiggling belly, bare feet on scales, X-ray results, sugary sodas, a pie in ...

Image Source: Zacks Investment Research. Meanwhile, HIMS is trading at a forward 12-month price-to-sales (P/S) ratio of 4.6X, above its median of 2.3X over the past three years.

Hims & Hers Health (NYSE: HIMS), a telehealth platform, experienced an 8% increase in its stock on Friday, May 30th, following the announcement of a 4% reduction in its workforce.

The companies engaged in an increasingly heated war of words on Monday following the drugmaker's decision to end a ...

The bundle will offer Novo Nordisk’s popular weight-loss drug at all its dosage strengths paired with a Hims & Hers membership providing "access to 24/7 care, ongoing clinical support, and ...

Image Source: Zacks Investment Research. Hims & Hers’ earnings surpassed the Zacks Consensus Estimate in two of the trailing four quarters, missed once and met in the other, the average surprise ...

Shares of Hims & Hers soared $4.21, or 29%, to $18.79 in Monday afternoon trading. GLP-1 drugs, which stands for glucagon-like peptide 1 agonists, help people feel fuller and less hungry, aiding ...

The stock price of Hims & Hers Health (NYSE: HIMS), a telehealth platform, has risen a solid 14% in a week. Much of this move came after the U.S. FDA asked for more time to confirm the shortage of ...